Reply To: Avacta

Nick Hargrave

More positive news from Avacta this morning as multi-billion dollar pharma company LG Chem extends license with a view to taking a second of Avacta’s platforms (Affirmers) into the clinic for in-human trials. A small payment in the grand scheme of things, but additional evidence of the potential value in the platforms